Antitumor activity of inhibiting SYK kinase with TAK-659, an investigational agent, in DLBCL models.Jessica J. Huck, Karuppiah Kannan, Matthew Theisen et al.|Journal of Clinical Oncology|2014Cited by 6
TAK-659 in combination with NKTR-214 and anti-PD-1 therapy leads to complete and sustained tumor regression and immune memory in pre-clinical syngeneic models.Jie Yu, Jonathan Zalevsky, Jessica Huck Sappal et al.|Journal of Clinical Oncology|2018Cited by 0